Singular Genomics Systems - OMIC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.68
  • Forecasted Upside: 70.89%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.40
▲ +0.01 (2.60%)

This chart shows the closing price for OMIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Singular Genomics Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMIC

Analyst Price Target is $0.68
▲ +70.89% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Singular Genomics Systems in the last 3 months. The average price target is $0.68, with a high forecast of $0.85 and a low forecast of $0.50. The average price target represents a 70.89% upside from the last price of $0.40.

This chart shows the closing price for OMIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Singular Genomics Systems. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2024UBS GroupBoost TargetNeutral ➝ Neutral$0.40 ➝ $0.50Low
1/22/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$0.95 ➝ $0.85Low
8/10/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$1.15 ➝ $1.00Low
11/8/2022The Goldman Sachs GroupLower TargetNeutral$3.50 ➝ $3.00Low
8/17/2022UBS GroupDowngradeBuy ➝ Neutral$10.00 ➝ $4.50Low
8/10/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$3.50Low
8/10/2022Bank of AmericaDowngradeBuy ➝ Underperform$3.00Low
7/14/2022The Goldman Sachs GroupLower TargetBuy$9.50 ➝ $5.00Low
4/13/2022The Goldman Sachs GroupLower TargetBuy$17.00 ➝ $11.00High
1/7/2022Bank of AmericaUpgradeNeutral ➝ Buy$21.00High
1/6/2022UBS GroupLower TargetBuy ➝ Buy$32.00 ➝ $25.00High
6/21/2021Bank of AmericaInitiated CoverageNeutral$26.00High
6/21/2021JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
6/21/2021CowenInitiated CoverageOutperformHigh
6/21/2021The Goldman Sachs GroupInitiated CoverageBuy$35.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Singular Genomics Systems logo
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Read More

Today's Range

Now: $0.40
Low: $0.38
High: $0.41

50 Day Range

MA: $0.51
Low: $0.38
High: $0.61

52 Week Range

Now: $0.40
Low: $0.31
High: $1.21

Volume

119,319 shs

Average Volume

115,164 shs

Market Capitalization

$29.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Singular Genomics Systems?

The following Wall Street analysts have issued stock ratings on Singular Genomics Systems in the last twelve months: The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for OMIC.

What is the current price target for Singular Genomics Systems?

2 Wall Street analysts have set twelve-month price targets for Singular Genomics Systems in the last year. Their average twelve-month price target is $0.68, suggesting a possible upside of 70.9%. The Goldman Sachs Group, Inc. has the highest price target set, predicting OMIC will reach $0.85 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $0.50 for Singular Genomics Systems in the next year.
View the latest price targets for OMIC.

What is the current consensus analyst rating for Singular Genomics Systems?

Singular Genomics Systems currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OMIC, but not buy more shares or sell existing shares.
View the latest ratings for OMIC.

What other companies compete with Singular Genomics Systems?

How do I contact Singular Genomics Systems' investor relations team?

Singular Genomics Systems' physical mailing address is 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The company's listed phone number is 858-333-7830. The official website for Singular Genomics Systems is singulargenomics.com. Learn More about contacing Singular Genomics Systems investor relations.